NCT06386146 - JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation | Biotech Hunter

Enrollment

144

Participants

Timeline

Start Date

July 24, 2024

Primary Completion Date

January 31, 2027

Study Completion Date

July 31, 2027

Conditions

Solid Tumors

Interventions

DRUG

JAB-30355

Oral administration

DRUG

JAB-30355

Oral administration

Trial Locations (13)

32771

RECRUITING

Research site, Lake Mary

37203

RECRUITING

Research Site, Nashville

44195

RECRUITING

Research site, Cleveland

44718

TERMINATED

Research site, Canton

63110

RECRUITING

Research site, St Louis

77030

RECRUITING

Research site, Houston

80218

RECRUITING

Research Site, Denver

100000

RECRUITING

Research Site, Beijing

100021

RECRUITING

Research Site, Beijing

100142

RECRUITING

Research Site, Beijing

200032

RECRUITING

Research Site, Shanghai

250117

NOT_YET_RECRUITING

Research Site, Jinan

510000

NOT_YET_RECRUITING

Research Site, Guangzhou